{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093930","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.606511+00:00","generated_at":"2026-05-31T11:09:30.472362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%","bullets":["GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.","Cash, equivalents and investments $186.2M; sufficient to fund operations into Q1 2026.","R&D expenses $34.7M (up $5.2M YoY); G&A expenses $6.9M (down $0.4M YoY).","ASPEN-06 Phase 2: Evo-TRP achieved 40.3% ORR vs 26.6% control; mDOR 15.7 vs 7.6 months in ITT.","Phase 3 registrational trial in gastric/GEJ cancer expected to initiate mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093930","json":"https://secwatch.observer/filing/0000950170-24-093930.json","markdown":"https://secwatch.observer/filing/0000950170-24-093930.md","text":"https://secwatch.observer/filing/0000950170-24-093930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/0000950170-24-093930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/alxo-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:09:30.472362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}